Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CONCERT PHARMACEUTICALS, INC.CNCE · Entity 115906 | Director | June 14, 2018 | June 18, 2018 |
| CYTOKINETICS INCCYTK · Entity 3528 | Director | July 15, 2025 | July 16, 2025 |
| Crinetics Pharmaceuticals, Inc.CRNX · Entity 3579 | Director | June 11, 2025 | June 13, 2025 |
| Ocera Therapeutics, Inc.OCRX · Entity 171193 | Director | December 11, 2017 | December 11, 2017 |
| SEELOS THERAPEUTICS, INC.APRI · Entity 93662 | Director | January 04, 2018 | January 08, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CONCERT PHARMACEUTICALS, INC.
Report date June 14, 2018 · Filed June 18, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Nonstatutory Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.59 · Expires 2028-06-13 | Direct | 10,000 |
Reported balance
After 2018-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-14 · Grant · Acquired 10,000 · Balance 10,000 F1: The shares underlying this option vest in equal quarterly installments over a one-year period, through and including June 14, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest in equal quarterly installments over a one-year period, through and including June 14, 2019.
CYTOKINETICS INC
Report date July 15, 2025 · Filed July 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,345 |
Reported balance
After 2025-07-15 transaction · row 1
1 source rowRow 1 · 2025-07-15 · Grant · Acquired 164 · Balance 32,345 F1: Director equity in lieu of cash retainer program. |
Filing footnotes · ownership attribution and instrument terms
F1: Director equity in lieu of cash retainer program.
Crinetics Pharmaceuticals, Inc.
Report date June 11, 2025 · Filed June 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 116,146 |
Reported balance
After 2025-06-11 transaction · row 1
1 source rowRow 1 · 2025-06-11 · Grant · Acquired 6,900 · Balance 116,146 F1: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.33 · Expires 2035-06-11 | Direct | 10,350 |
Reported balance
After 2025-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-11 · Grant · Acquired 10,350 · Balance 10,350 F2: The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
F2: The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
Ocera Therapeutics, Inc.
Report date December 11, 2017 · Filed December 11, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-12-11 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2017-12-11 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the "Merger Agreement"), by and between Ocera Therapeutics, Inc., a Delaware corporation (the "Issuer"), MAK LLC, a Delaware limited liability company ("Parent"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent ("Purchaser"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser ("Mallinckrodt"), Purchaser was merged with and into Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares of common stock, $0.00001 par value per share (the "Shares"), of the Issuer outstanding immediately prior to the effective time of the Merger (the "Effective Time") , were canceled and converted automatically and without any required action on the part of the Reporting Person into the right to receive (i) $1.52 per Share in cash, without interest, plus (ii) one non-transferable contingent value right per Share (each, a "CVR"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt (the "CVR Agreement"), entered into on December 7, 2017 to receive one or more payments in cash currently estimated to be up to $2.58 per Share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-12-11 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2017-12-11 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the "Merger Agreement"), by and between Ocera Therapeutics, Inc., a Delaware corporation (the "Issuer"), MAK LLC, a Delaware limited liability company ("Parent"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent ("Purchaser"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser ("Mallinckrodt"), Purchaser was merged with and into Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares of common stock, $0.00001 par value per share (the "Shares"), of the Issuer outstanding immediately prior to the effective time of the Merger (the "Effective Time") , were canceled and converted automatically and without any required action on the part of the Reporting Person into the right to receive (i) $1.52 per Share in cash, without interest, plus (ii) one non-transferable contingent value right per Share (each, a "CVR"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt (the "CVR Agreement"), entered into on December 7, 2017 to receive one or more payments in cash currently estimated to be up to $2.58 per Share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes. F3: At the Effective Time of the Merger, each restricted stock unit outstanding, automatically and without any required action on the part of the Reporting Person, became fully vested and canceled in exchange for a right to receive, for each share of common stock underlying the restricted stock unit, (i) an amount in cash, equal to $1.52, without interest plus (ii) one CVR, less any required withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.25 · Expires 2023-12-19 | Direct | 0 |
Reported balance
After 2017-12-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-12-11 · Disposition to issuer · Disposed 20,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR. F5: (Continued from Footnote 4) All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore. F6: This Out of the Money Option, which provided for vesting with respect to 25% of such options on December 19, 2014, with the remaining 75% of such options vesting in equal monthly installments over the next succeeding three year period, was cancelled in connection with the Merger for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.84 · Expires 2024-06-11 | Direct | 0 |
Reported balance
After 2017-12-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-12-11 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR. F5: (Continued from Footnote 4) All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore. F7: This Out of the Money Option, which became fully vested on July 11, 2015, was cancelled in connection with the Merge for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.76 · Expires 2025-06-17 | Direct | 0 |
Reported balance
After 2017-12-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-12-11 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR. F5: (Continued from Footnote 4) All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore. F8: This Out of the Money Option, which became fully vested on June 18, 2016, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $3.76, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.26 · Expires 2026-06-13 | Direct | 0 |
Reported balance
After 2017-12-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-12-11 · Disposition to issuer · Disposed 12,500 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR. F5: (Continued from Footnote 4) All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore. F9: This Out of the Money Option, which became fully vested on June 14, 2017, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $2.26, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the "Merger Agreement"), by and between Ocera Therapeutics, Inc., a Delaware corporation (the "Issuer"), MAK LLC, a Delaware limited liability company ("Parent"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent ("Purchaser"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser ("Mallinckrodt"), Purchaser was merged with and into Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger").
F2: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares of common stock, $0.00001 par value per share (the "Shares"), of the Issuer outstanding immediately prior to the effective time of the Merger (the "Effective Time") , were canceled and converted automatically and without any required action on the part of the Reporting Person into the right to receive (i) $1.52 per Share in cash, without interest, plus (ii) one non-transferable contingent value right per Share (each, a "CVR"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt (the "CVR Agreement"), entered into on December 7, 2017 to receive one or more payments in cash currently estimated to be up to $2.58 per Share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes.
F3: At the Effective Time of the Merger, each restricted stock unit outstanding, automatically and without any required action on the part of the Reporting Person, became fully vested and canceled in exchange for a right to receive, for each share of common stock underlying the restricted stock unit, (i) an amount in cash, equal to $1.52, without interest plus (ii) one CVR, less any required withholding taxes.
F4: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR.
F5: (Continued from Footnote 4) All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore.
F6: This Out of the Money Option, which provided for vesting with respect to 25% of such options on December 19, 2014, with the remaining 75% of such options vesting in equal monthly installments over the next succeeding three year period, was cancelled in connection with the Merger for no consideration.
F7: This Out of the Money Option, which became fully vested on July 11, 2015, was cancelled in connection with the Merge for no consideration.
F8: This Out of the Money Option, which became fully vested on June 18, 2016, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $3.76, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.
F9: This Out of the Money Option, which became fully vested on June 14, 2017, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $2.26, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.
SEELOS THERAPEUTICS, INC.
Report date January 04, 2018 · Filed January 08, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.11 · Expires 2028-01-04 | Direct | 35,000 |
Reported balance
After 2018-01-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-04 · Grant · Acquired 35,000 · Balance 35,000 F1: The options to purchase shares of common stock were issued to the Reporting Person, a non-employee director of Issuer, as an annual stock option grant for his service as a director of the Issuer. F2: The options shall vest with respect to 1/12th of the underlying shares monthly, commencing with the first monthly vesting date of February 4, 2018, so that such options are fully vested on January 4, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The options to purchase shares of common stock were issued to the Reporting Person, a non-employee director of Issuer, as an annual stock option grant for his service as a director of the Issuer.
F2: The options shall vest with respect to 1/12th of the underlying shares monthly, commencing with the first monthly vesting date of February 4, 2018, so that such options are fully vested on January 4, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2025 Filed Jul 16, 2025 21:44 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 164 | $38.01 | $6,233.64 |
DisclosureSEC source: 0001127602-25-019290 · form4.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,345 F1 · kind: Director equity in lieu of cash retainer program. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:30 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (right to buy) · Derivative | 10,350 | $0.00 Strike: $32.33 | $0.00 |
DisclosureSEC source: 0000950170-25-086260 · ownership.xml · derivative · entry 2 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,350 Underlying: Common Stock · 10,350 shares Expires 2035-06-11 F2 · derivative.exercise_date: The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:30 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantCommon Stock | 6,900 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-086260 · ownership.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,146 F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| May 14, 2025 Filed May 14, 2025 23:25 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 10,880 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001127602-25-014355 · form4.xml · derivative · entry 2 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,880 Underlying: Common Stock · 10,880 shares Expires 2035-05-13 F2 · kind: Comprised of stock options that will vest monthly in equal installments over a period commencing on the grant date and ending on the earlier to occur of (x) the one-year anniversary of the date of the grant and (y) the date of the issuer's annual meeting of stockholders for the calendar year immediately subsequent to the grant date, subject to the director's continuous service as a member of the issuer's Board of Directors. Read SEC document |
| May 14, 2025 Filed May 14, 2025 23:25 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 7,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-014355 · form4.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,181 F1 · kind: Comprised of restricted stock units ("RSUs") that will vest in one installment on the earlier to occur of (x) the one-year anniversary of the grant date and (y) the date of the issuer's annual meeting of stockholders for the calendar year immediately subsequent to the grant date, subject to the director's continuous service as a member of the issuer's Board of Directors. RSUs convert to shares of common stock on a 1:1 basis upon vesting. Read SEC document |
| April 21, 2025 Filed Apr 21, 2025 21:42 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $6.21 | $0.00 |
DisclosureSEC source: 0001127602-25-012398 · form4.xml · derivative · entry 3 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2025-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on May 20, 2016. Read SEC document |
| April 21, 2025 Filed Apr 21, 2025 21:42 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 20,000 | $38.46 | $769,200.00 |
DisclosureSEC source: 0001127602-25-012398 · form4.xml · nonDerivative · entry 2 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,848 Read SEC document |
| April 21, 2025 Filed Apr 21, 2025 21:42 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 20,000 | $6.21 | $124,200.00 |
DisclosureSEC source: 0001127602-25-012398 · form4.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,848 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2025 Filed Apr 16, 2025 20:04 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 162 | $38.56 | $6,246.72 |
DisclosureSEC source: 0001127602-25-012113 · form4.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,848 F1 · kind: Shares acquired pursuant to Director Stock in lieu of Cash Retainer Program. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:22 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 127 | $48.93 | $6,214.11 |
DisclosureSEC source: 0001127602-25-000758 · form4.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,686 F1 · kind: Director Stock in Lieu of Cash Retainer Program Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 00:23 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 742 | $0.00 Strike: $7.37 | $0.00 |
DisclosureSEC source: 0001127602-24-029523 · form4.xml · derivative · entry 3 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 742 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option shall vest and become exercisable as to 5,936 shares divided into equal monthly installments such that the option shall be 100% vested on January 2, 2016. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 00:23 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 742 | $48.61 | $36,068.62 |
DisclosureSEC source: 0001127602-24-029523 · form4.xml · nonDerivative · entry 2 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,559 Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 00:23 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 742 | $7.37 | $5,468.54 |
DisclosureSEC source: 0001127602-24-029523 · form4.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2024 Filed Nov 26, 2024 22:38 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 742 | $0.00 Strike: $7.37 | $0.00 |
DisclosureSEC source: 0001127602-24-028124 · form4.xml · derivative · entry 3 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 742 Underlying: Common Stock · 742 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option shall vest and become exercisable as to 5,936 shares divided into equal monthly installments such that the option shall be 100% vested on January 2, 2016. Read SEC document |
| November 25, 2024 Filed Nov 26, 2024 22:38 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 742 | $50.00 | $37,100.00 |
DisclosureSEC source: 0001127602-24-028124 · form4.xml · nonDerivative · entry 2 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,559 Read SEC document |
| November 25, 2024 Filed Nov 26, 2024 22:38 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 742 | $7.37 | $5,468.54 |
DisclosureSEC source: 0001127602-24-028124 · form4.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 28, 2024 Filed Oct 31, 2024 20:49 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 4,452 | $0.00 Strike: $7.37 | $0.00 |
DisclosureSEC source: 0001127602-24-026161 · form4.xml · derivative · entry 3 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,484 Underlying: Common Stock · 4,452 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option shall vest and become exercisable as to 5,936 shares divided into equal monthly installments such that the option shall be 100% vested on January 2, 2016. Read SEC document |
| October 28, 2024 Filed Oct 31, 2024 20:49 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 4,452 | $52.25 | $232,617.00 |
DisclosureSEC source: 0001127602-24-026161 · form4.xml · nonDerivative · entry 2 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,559 Read SEC document |
| October 28, 2024 Filed Oct 31, 2024 20:49 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 4,452 | $7.37 | $32,811.24 |
DisclosureSEC source: 0001127602-24-026161 · form4.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,011 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 21:25 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 118 | $52.60 | $6,206.80 |
DisclosureSEC source: 0001127602-24-025194 · form4.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,559 F1 · kind: Stock award in lieu of cash retainer payment. Read SEC document |
| July 01, 2024 Filed Jul 4, 2024 00:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 114 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-020149 · form4.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,441 F1 · kind: Stock award in lieu of cash retainer payment. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:18 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $44.71 | $0.00 |
DisclosureSEC source: 0000950170-24-071921 · ownership.xml · derivative · entry 2 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-06-07 F2 · derivative.exercise_date: The stock option shall vest and become exercisable on the earlier of the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:18 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantCommon Stock | 3,400 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-071921 · ownership.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,246 F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| May 15, 2024 Filed May 16, 2024 22:00 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 3,636 | $0.00 Strike: $60.50 | $0.00 |
DisclosureSEC source: 0001127602-24-015719 · form4.xml · derivative · entry 2 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,636 Underlying: Common Stock · 3,636 shares Expires 2034-05-15 Read SEC document |
| May 15, 2024 Filed May 16, 2024 22:00 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 5,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-015719 · form4.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,327 Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 21:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 74 | $84.12 | $6,224.88 |
DisclosureSEC source: 0001127602-24-000433 · form4.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,727 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are fully vested from the moment of grant. Shares issued at per share price of $84.12, representing the Issuer's closing stock price on January 2, 2024. Read SEC document |
| December 27, 2023 Filed Dec 27, 2023 21:11 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001127602-23-030485 · form4.xml · derivative · entry 6 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2024-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 7, 2023. F2 · derivative.exercise_date: This option shall vest and become exercisable as to 10,000 shares divided into equal monthly installments such that the option shall be 100% vested on May 21, 2015. Read SEC document |
| December 27, 2023 Filed Dec 27, 2023 21:11 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001127602-23-030485 · form4.xml · derivative · entry 5 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2024-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 7, 2023. F2 · derivative.exercise_date: This option shall vest and become exercisable as to 10,000 shares divided into equal monthly installments such that the option shall be 100% vested on May 21, 2015. Read SEC document |
| December 27, 2023 Filed Dec 27, 2023 21:11 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 5,000 | $73.60 | $368,000.00 |
DisclosureSEC source: 0001127602-23-030485 · form4.xml · nonDerivative · entry 4 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,653 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 7, 2023. Read SEC document |
| December 27, 2023 Filed Dec 27, 2023 21:11 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 5,000 | $4.44 | $22,200.00 |
DisclosureSEC source: 0001127602-23-030485 · form4.xml · nonDerivative · entry 3 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,653 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 7, 2023. Read SEC document |
| December 27, 2023 Filed Dec 27, 2023 21:11 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 5,000 | $73.60 | $368,000.00 |
DisclosureSEC source: 0001127602-23-030485 · form4.xml · nonDerivative · entry 2 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,653 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 7, 2023. Read SEC document |
| December 27, 2023 Filed Dec 27, 2023 21:11 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 5,000 | $4.44 | $22,200.00 |
DisclosureSEC source: 0001127602-23-030485 · form4.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,653 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on September 7, 2023. Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 20:15 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 448 | $27.88 | $12,490.24 |
DisclosureSEC source: 0001127602-23-025166 · form4.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,653 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $27.88, representing the Issuer's closing stock price on October 2, 2023. Read SEC document |
| August 21, 2023 Filed Aug 21, 2023 20:01 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 6,020 | $0.00 Strike: $6.72 | $0.00 |
DisclosureSEC source: 0001127602-23-023012 · form4.xml · derivative · entry 3 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,020 shares Expires 2024-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2023 Filed Aug 21, 2023 20:01 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 6,020 | $32.02 | $192,760.40 |
DisclosureSEC source: 0001127602-23-023012 · form4.xml · nonDerivative · entry 2 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,205 Read SEC document |
| August 21, 2023 Filed Aug 21, 2023 20:01 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 6,020 | $6.72 | $40,454.40 |
DisclosureSEC source: 0001127602-23-023012 · form4.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 20:24 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 374 | $33.36 | $12,476.64 |
DisclosureSEC source: 0001127602-23-020064 · form4.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,205 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $33.36, representing the Issuer's closing stock price on July 3, 2023. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 21:00 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $20.32 | $0.00 |
DisclosureSEC source: 0001209191-23-038827 · doc4.xml · derivative · entry 2 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2033-06-15 F2 · derivative.exercise_date: The stock option shall vest and become exercisable on the earlier of the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 21:00 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-038827 · doc4.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,846 F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| May 10, 2023 Filed May 18, 2023 21:13 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $37.89 | $0.00 |
DisclosureSEC source: 0001127602-23-016196 · form4.xml · derivative · entry 2 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-05-10 F2 · kind: Options shall vest and become exercisable in 12 equal monthly installments, the first such installment vesting on 06/10/2023 and the last such installment vesting on 05/10/2024. Read SEC document |
| May 10, 2023 Filed May 18, 2023 21:13 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-016196 · form4.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,831 F1 · kind: Comprised of restricted stock units that will vest in full and in one installment on 05/10/2024. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 20:04 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 298 | $37.71 | $11,237.58 |
DisclosureSEC source: 0001127602-23-012541 · form4.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,831 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of director's annual base retainer program. Shares are fully vested from the moment of grant. Shares are issued at per share price of $37.71, representing the closing stock price of the Issuer's common stock on April 3, 2023. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:01 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $6.72 | $0.00 |
DisclosureSEC source: 0001127602-23-003984 · form4.xml · derivative · entry 3 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,020 Underlying: Common Stock · 7,000 shares Expires 2024-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on November 8, 2022. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:01 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 7,000 | $45.00 | $315,000.00 |
DisclosureSEC source: 0001127602-23-003984 · form4.xml · nonDerivative · entry 2 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,533 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on November 8, 2022. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:01 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 7,000 | $6.72 | $47,040.00 |
DisclosureSEC source: 0001127602-23-003984 · form4.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,533 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on November 8, 2022. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 23:40 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 253 | $44.35 | $11,220.55 |
DisclosureSEC source: 0001127602-23-000714 · form4.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,533 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $44.35, representing the Issuer's closing stock price on January 3, 2023. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:23 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 110 | $51.11 | $5,622.10 |
DisclosureSEC source: 0001127602-22-023701 · form4.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,280 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are fully vested from the moment of grant. Shares are issued at per share price of $51.11, representing the closing stock price of the Issuer's common stock on October 3, 2022. Read SEC document |
| September 01, 2022 Filed Sep 1, 2022 22:19 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 4,166 | $0.00 Strike: $6.78 | $0.00 |
DisclosureSEC source: 0001127602-22-021922 · form4.xml · derivative · entry 3 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,166 shares Expires 2023-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on July 1, 2022. Read SEC document |
| September 01, 2022 Filed Sep 1, 2022 22:19 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 4,166 | $52.79 | $219,923.14 |
DisclosureSEC source: 0001127602-22-021922 · form4.xml · nonDerivative · entry 2 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,170 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on July 1, 2022. Read SEC document |
| September 01, 2022 Filed Sep 1, 2022 22:19 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 4,166 | $6.78 | $28,245.48 |
DisclosureSEC source: 0001127602-22-021922 · form4.xml · nonDerivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,336 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on July 1, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.